Table 1 Clinico-pathological characteristics of the samples used for UTUC PDX.
Variable | PDX growth (N = 17) | No PDX growth (N = 17) | P-value |
|---|---|---|---|
Median age at surgery, years (IQR) | 69.6 (65.7–75.7) | 65.6 (60.0–75.3) | 0.390 |
Gender | 1.000 | ||
Male | 11 (64.7) | 11 (64.7) | |
Female | 6 (35.3) | 6 (35.3) | |
Lynch syndrome/MSI-H | 0.166 | ||
Yes | 4 (23.5) | 1 (5.9) | |
No | 12 (70.6) | 16 (94.1) | |
Not tested | 1 (5.9) | 0 (0) | |
Smoking status | 0.039 | ||
Current/former | 10 (58.8) | 16 (94.1) | |
Never | 7 (41.2) | 1 (5.9) | |
Prior history of urothelial cancer | 1.000 | ||
Yes | 5 (29.4) | 6 (35.3) | |
No | 12 (70.6) | 11 (64.7) | |
Location of primary tumor | 1.000 | ||
Renal pelvis | 15 (88.2) | 14 (82.4) | |
Ureter | 2 (11.8) | 3 (17.6) | |
Specimen type | 0.6a | ||
Primary | 14 (82.4) | 16 (94.1) | |
Lymph node | 1 (5.9) | 0 (0) | |
Distant metastasis | 2 (11.8) | 0 (0) | |
Endoscopic biopsy | 0 (0) | 1 (5.9) | |
Grade | 0.480 | ||
Low | 2 (11.8) | 0 (0) | |
High | 15 (88.2) | 17 (100) | |
pT stage | 0.166 | ||
<pT2 (non-invasive) | 5 (29.4) | 10 (58.8) | |
≥pT2 (invasive) | 12 (70.6) | 7 (41.2) | |
pN stage | 0.460 | ||
pN0 | 10 (58.8) | 13 (70.5) | |
pN+ | 5 (29.4) | 2 (11.8) | |
pNx | 2 (11.8) | 2 (11.8) | |
Prior chemotherapy | 0.688 | ||
Yes | 3 (17.6) | 5 (29.4) | |
No | 14 (82.4) | 12 (70.6) |
